Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.80 +0.42 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,393,750
Open 40.55
Bid (Size) 40.75 (7)
Ask (Size) 40.79 (8)
Prev. Close 40.38
Today's Range 40.28 - 40.83
52wk Range 39.23 - 56.32
Shares Outstanding 5,606,688,356
Dividend Yield 3.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Surprisingly Underrated Stocks to Buy in April
These drugmakers could deliver greater gains than many investors expect. 
Via The Motley Fool
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),... 
Via Benzinga

Performance

YTD
-20.41%
-20.41%
1 Month
+1.54%
+1.54%
3 Month
-20.37%
-20.37%
6 Month
-6.76%
-6.76%
1 Year
-21.19%
-21.19%

More News

Read More
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Via Benzinga
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
Via Benzinga
Pfizer Unusual Options Activity
Via Benzinga
Bear of the Day: BioNTech
Via Talk Markets
Bear of the Day: Pfizer Inc.
Via Talk Markets
If You Invested $25,000 in Pfizer in 2020, This Is How Much You Would Have Today
Via The Motley Fool
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
Via The Motley Fool
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
Via Benzinga
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out
Via Investor's Business Daily
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Via The Motley Fool
Better Growth Stock: AbbVie vs. Pfizer
Via The Motley Fool
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Via MarketBeat
2 Dividend Stocks Down 11% to 22% to Buy and Hold Forever
Via The Motley Fool
Don't Be Fooled by These 3 Value Traps
Via MarketBeat
This entertainer is taking her shot at some new things — and doesn’t want pneumococcal pneumonia to stand in her way
Via Brandpoint
Smartsheet Can Bolster Workflow Ecosystems and Your Portfolio
Via MarketBeat
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
2 Rock Solid Dividend Stocks to Buy on the Dip
Via The Motley Fool
BioNTech Is Ripe For A Rebound In 2023
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion
Via Investor's Business Daily
3 Low P/E Stocks That Are Bound to Rebound This Year
Via InvestorPlace
Could CRISPR Therapeutics Become the Next Moderna?
Via The Motley Fool
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.